Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer

Background: Salvage chemotherapy is the mainstay of treatment for metastatic gastric cancer (mGC). This study aimed to clarify the effects of palliative gastrectomy (PG) and identify prognostic factors in mGC patients undergoing PG. Methods: This was a retrospective review of 333 mGC patients receiving PG or a non-resection procedure (NR) between 2000 and 2010. Clinicopathological factors affecting the prognosis of these patients were collected prospectively and analyzed. Results: One hundred and ninety-three patients underwent PG and 140 NR. The clinicopathological characteristics were comparable between the two groups except for metastatic pattern. There were no significant differences in postoperative morbidity and mortality between the two groups. The PG group had a significantly longer median overall survival compared with the NR group (7.7 months vs. 4.9 months). In the PG group, age <= 58 years, preoperative albumin level > 3 g/dL, ratio of metastatic to examined lymph nodes <= 0.58, and administration of chemotherapy were independent prognostic factors in multivariate analysis. Conclusions: Patients undergoing PG had better outcomes than those undergoing NR. Among the patients undergoing resection, age <= 58 years, a better preoperative nutritional status, less nodal involvement and postoperative chemotherapy independently affected patient survival.